Mainz Biomed B.V. (MYNZ) Earnings History
Net Loss6 years of earnings data (2019–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Mainz Biomed B.V. (MYNZ) Earnings Overview
As of June 25, 2026, Mainz Biomed B.V. (MYNZ) reported trailing twelve-month net income of -$40M, reflecting -1280.2% year-over-year growth. The company earned $-41.42 per diluted share over the past four quarters, with a net profit margin of -2421.8%.
Looking at the long-term picture, MYNZ's historical earnings data spans multiple years. The company achieved its highest annual net income of -$586,895 in fiscal 2020.
Mainz Biomed B.V. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EXAS (-$208M net income, -6.4% margin), GKOS (-$189M net income, -37.0% margin), NTRA (-$226M net income, -9.0% margin), MYNZ has room to improve margins relative to the peer group. Compare MYNZ vs EXAS →
MYNZ Earnings vs Peers
Earnings metrics vs comparable public companies
MYNZ Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$22M | +17.7% | -$19M | $-22.36 | -2421.8% | -2091.2% |
| 2023 | -$26M | +0.6% | -$27M | $-1.62 | -2936.5% | -2975.5% |
| 2022 | -$26M | -126.3% | -$26M | $-1.87 | -4992.2% | -4990.6% |
| 2021 | -$12M | -1891.9% | -$10M | $-1.67 | -2024.8% | -1684.4% |
| 2020 | $-586,895 | +38.7% | $-766,090 | $-0.05 | -118.9% | -155.2% |
| 2019 | $-957,055 | - | $-921,909 | $-0.10 | -340.1% | -327.6% |
Download Data
Export MYNZ earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MYNZ — Frequently Asked Questions
Quick answers to the most common questions about buying MYNZ stock.
What is MYNZ earnings per share (EPS)?
MYNZ trailing twelve-month (TTM) diluted EPS is $-41.42, reflecting -1280.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2024 is available in the table on this page.
What is Mainz Biomed B.V.'s net income?
Mainz Biomed B.V. (MYNZ) trailing twelve-month net income is $-40M as of 2024. Earnings declined -1280.2% year-over-year.
Is MYNZ profitable?
MYNZ is not currently profitable on a TTM basis, reporting a net loss of $-40M. Net margin is -2421.8%. Investors should monitor for a return to profitability.
What is MYNZ's earnings growth rate?
MYNZ compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2024.
What are MYNZ's profit margins?
Mainz Biomed B.V. net profit margin is -2421.8%, operating margin is -2091.2%, and gross margin is +64.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -465.8%.
Is MYNZ growing earnings?
MYNZ earnings are declining — EPS fell -1280.2% year-over-year. TTM net income dropped to $-40M. This contrasts with the 5-year CAGR of N/A.
What was MYNZ's best earnings year?
Mainz Biomed B.V.'s highest annual net income on record is $-586895.00, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2024 and includes all annual and quarterly figures.
What were MYNZ's earnings last quarter?
MYNZ's most recent reported quarter was Q4 2024. Net income was $-11M with diluted EPS of $-7.71. For a full breakdown of all quarters, see the quarterly earnings table on this page.